In addition to PD-1/PD-L1 blockade, CTLA-4 inhibition is being explored, with the anti-CTLA-4 monoclonal antibody ipilimumab, which shows promise in the treatment of melanoma brain metastases. The gene discussed is CTLA4; the disease is melanoma.